Details of the Drug Formulations

General Information of Drug (ID: DM0C9IL)

Drug Name
Ranolazine Drug Info
Synonyms
RANOLAZINE; 95635-55-5; Ranexa; N-(2,6-dimethylphenyl)-2-(4-(2-hydroxy-3-(2-methoxyphenoxy)propyl)piperazin-1-yl)acetamide; CVT-303; (-)-Ranolazine; Ranolazine (Ranexa); Ranolazine 2HCl; RS-43285-003; 142387-99-3; N-(2,6-dimethylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]acetamide; CHEBI:87690; N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide; C24H33N3O4; NCGC00015897-02; DSSTox_RID_80743; DSSTox_CID_25196; DSSTox_GSID_45196; Ran4; CVT 303; Latixa; RAN D; Latixa; Ranolazine dihydrochloride; KEG-1295; RS-43285; Ranexa (TN); Ranexa, Ranolazine; Ranolazine (USAN/INN); Ranolazine extended-release; Ranolazine/Dronedarone Fixed-Dose Combination
Indication
Disease Entry ICD 11 Status REF
Acute coronary syndrome BA41 Approved [1]
Angina pectoris BA40 Approved [1]
Chronic/stable angina BA40.1 Approved [2]
Diarrhea-predominant irritable bowel syndrome DD91.01 Approved [1]
Paroxysmal atrial fibrillation BC81.30 Phase 2 [3]
Therapeutic Class
Analgesics
Cross-matching ID
PubChem CID
56959
ChEBI ID
CHEBI:87690
CAS Number
95635-55-5
TTD ID
D03HYQ
VARIDT ID
DR00246
INTEDE ID
DR1394
ACDINA ID
D00584

Full List of Drug Formulations Containing This Drug

Ranolazine 500 mg tablet
Company Formulation ID FDA Description
Gilead Sciences F18884 Fd&c yellow no. 6; Magnesium stearate; Sodium hydroxide; Titanium dioxide; Polyethylene glycol 400; Polysorbate 80; Aluminum oxide; Carnauba wax; Cellulose, microcrystalline; Hypromellose 2910 (3 cps); Hypromellose 2910 (5 cps); Hypromellose 2910 (6 cps); Methacrylic acid - ethyl acrylate copolymer (1:1) type a
Aphena Pharma Solutions-Tennessee; Cardinal Health; Carilion Materials Management; Gilead Sciences F18883 Magnesium stearate; Ferric oxide red; Ferric oxide yellow; Sodium hydroxide; Talc; Titanium dioxide; Water; Polyethylene glycol 3350; Polyvinyl alcohol; Carnauba wax; Cellulose, microcrystalline; Hypromelloses; Methacrylic acid - ethyl acrylate copolymer (1:1) type a
Cardinal Health F18885 Magnesium stearate; Ferric oxide red; Ferric oxide yellow; Sodium hydroxide; Talc; Titanium dioxide; Polyethylene glycol 400; Polyvinyl alcohol; Carnauba wax; Cellulose, microcrystalline; Hypromellose 2910 (5 mpa.s); Methacrylic acid - ethyl acrylate copolymer (1:1) type a
------------------------------------------------------------------------------------
Ranolazine 1000 mg tablet
Company Formulation ID FDA Description
Gilead Sciences F18881 Lactose monohydrate; Magnesium stearate; Ferric oxide yellow; Sodium hydroxide; Titanium dioxide; Triacetin; Water; Polyethylene glycol 3350; Carnauba wax; Cellulose, microcrystalline; Hypromellose 2910 (6 mpa.s); Hypromelloses; Methacrylic acid - ethyl acrylate copolymer (1:1) type a
Gilead Sciences F18882 Lactose monohydrate; Magnesium stearate; Ferric oxide yellow; Sodium hydroxide; Titanium dioxide; Triacetin; Polyethylene glycol 3350; Carnauba wax; Cellulose, microcrystalline; Hypromellose 2910 (5 cps); Hypromellose 2910 (6 cps); Methacrylic acid - ethyl acrylate copolymer (1:1) type a
------------------------------------------------------------------------------------

References

1 Ranolazine FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7291).
3 Clinical pipeline report, company report or official report of Gilead.